中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2013, Vol. 48 Issue (6) :482-484    DOI: 10.11669/cpj.2013.06.020
��Դ����� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << | >>
��ЧҺ��ɫ�״������׷��ⶨ��Һ�а���͡Ũ��
�賤��1a,ŷ����2,��ʤ��1b*,������1c,������1c
1.������ѧ�����۶��Ǻ��ҽԺ,a.���Ǻ��;b.���ƿ�;c.ҩ����,�Ϻ� 200031;2.�Ϻ������������ҽԺ����ʵ����,�Ϻ� 200031
LI Chang-jiang1a,OU Mei-xian2,WANG Sheng-zi1b*,HUANG Tao-min1c,CHEN Nian-zu1c
a Department of Otorhinolaryngology;b Department of Radiation Oncology;c Department of Pharmacy;1 Eye Ear Nose Throat Hospital of Fudan University,Shanghai 200031,China;2 Central Laboratory,Shanghai Xuhui Central Hospital,Shanghai 200031,China

Download: PDF (601KB)   HTML (1KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ Ŀ�� ������ЧҺ��ɫ�״�������(HPLC-MS/MS)ֱ�Ӽ����Һ�а���͡(amifostine,AMI)�ķ��������� �ռ�6λ��������־Ը����ҺΪ����,ʯɼ��ף�huperzine-A,HupA��Ϊ�ڱ�,���õ��׳���,�ø�ЧҺ��ɫ�״������ײⶨ��Һ�еİ���͡��ɫ����ΪZIC-HILIC��ˮɫ�׷�������2.1 mm×100 mm,3.5 μm��,���׷������ö෴Ӧ���ɨ��ģʽ��MRM��,����ԴΪ����������Դ��ESI������� ����͡����Һ�м�⵽�����Է�ΧΪ0.938��30 mg·L-1 ,���Թ�ϵ����,���ʹ�����Ϊ��y=0.072x-0.005 26 (r=0.999 1) (n=6),��������Ϊ0.938 mg·L-1(S/N>10)����Һ��Ʒ�ĵ͡��С���3���ʿ�Ũ�ȣ�1.0��5.0��25 mg·L-1�����ڡ����侫�ܶ�(RSD)��С��15%,�䷽�������ʾ�����85%������ ��ʵ���������İ���͡��ⷽ��ֱ�ӡ���ݡ���㡢�����ȸ߼����Ժ�,��������Һ�а���͡�IJⶨ����ѧ�о���
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
�賤��a
ŷ����
��ʤ��b*
������c
������c
�ؼ����� ��ЧҺ��ɫ���������÷�    ����͡    ��Һ     
Abstract�� Objective To establish an HPLC-MS/MS method (high performance liquid chromatography-tandem mass spectrometry) for the direct determination of amifostine in human saliva. METHODS Saliva samples were collected from six adult healthy volunteers. After protein precipitation and addition of the internal standard (IS) huperzine-A (HupA),HPLC- MS/MS was used to analyze amifostine. The analysis was conducted using a ZIC�k-HILIC analytical column (2.1 mm×100 mm,3.5 μm). Electrospray ionization was used with multiple reaction monitoring (MRM) mode. RESULTS The lower limit of quantification (LLOQ) of the method was 0.938 mg·L-1 (S/N>10). The standard curve was linear in the range of 0.938-30 mg·L-1 (r=0.999 1,n=6). The inter-day and intra-day RSDs were all less than 15% for the low,medium and high concentration quality control samples (1.0,5.0 and 25 mg·L-1 ). The values of recovery were all more than 85%. CONCLUSION The method is direct,rapid,simple and sensitive,and suitable for the determination of amifostine in saliva samples.
Keywords�� HPLC -MS/MS ,   amifostine ,   saliva     
�ո�����: 2012-09-05;
ͨѶ���� ��ʤ��,Ů,��ʿ,����ҽʦ,��ʿ����ʦ �о�����ͷ�����������ƺͷ��������о� Tel/����021��64377134 Fax����021��64377151E-mail��shengzi_wang@yahoo.com.cn��ЧҺ��ɫ�״������׷��ⶨ��Һ�а���͡Ũ���賤��1a     Email: cpjtian@163.com
���߼��: �賤��,��,˶ʿ �о�����ͷ�����������������о�,ŷ����,Ů,˶ʿ�����е�1���ߣ� �о�����ҩ����� ͨѶ���ߣ���ʤ��,Ů,��ʿ,����ҽʦ,��ʿ����ʦ �о�����ͷ�����������ƺͷ��������о� Tel/����021��64377134 Fax����021��64377151E-mail��shengzi_wang@yahoo.com.cn
���ñ���:   
�賤��a, ŷ����, ��ʤ��b*�� .��ЧҺ��ɫ�״������׷��ⶨ��Һ�а���͡Ũ��[J]  �й�ҩѧ��־, 2013,V48(6): 482-484
LI Chang-Jiang-a, ŷMei-Xian-, WANG Sheng-Zi-b* etc .Determination of Amifostine in Human Saliva by HPLC-MS/MS[J]  Chinese Pharmaceutical Journal, 2013,V48(6): 482-484
��
[1] MESSMER M B,THOMSEN A,KIRSTE S,et al. Xerostomia after radiotherapy in the head & neck area: Long-term observations. Radiother Oncol,2011,98��1��:48-50.
[2] RADES D,FEHLAUER F,BAJROVIC A,et al. Serious adverse effects of amifostine during radiotherapy head and neck cancer patients. Radiother Oncol,2004,70��4��:261-264.
[3] BARDET E,MARTIN L,CALAIS G,et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: Final Results of the GORTEC 2000-02 Phase III Randomized Trial. J Clin Oncol,2011,29��5��:127-133.
[4] UZAL M C,SEZER A,USTA U,et al. The protective effect of amifostine on radiation-induced proctitis: Systemic versus topical application. Balkan Med J,2012,29��1��:32-38.
[5] SIMONE N L,MENARD C,SOULE B P,et al. Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score. Int J Radiat Oncol Biol Phys,2008,70(1):90-95.
[6] BAI F,KIRSTEIN M N,HANNA S K,et al. New liquid chromatographic assay with electrochemical detection for the measurement of amifostine and WR1065. J Chromatogr B Analyt Technol Biomed Life Sci,2002,772��2��:257-265.
[7] SOUID A K,NEWTON G L,DUBOWY R L,et al. Determination of the cytoprotective agent WR-2721 (Amifostine,Ethyol) and its metabolites in human blood using monobromobimane fluorescent labeling and high-performance liquid chromatography. Cancer Chemother Pharmacol,1998,42��5��:400-406.
[8] MANDAL T K,WOMACK I. HPLC Analysis of amifostine. Pharm Pharmacol Commun,1999,5��9��:541-543.
[9] SWYNNERTON N F,MCGOVERN E P,NINO J A,et al. An improved HPLC assay for S-2-(3-aminopropylamino) ethyl phosphorothioate(WR-2721) in plasma. Int J Radiat Oncol Biol Phys,1984,10��9��:1521-1524.
[10] MANK A J,YEUNG E S. Diode laser-induced fluorescence detection in capillary electrophoresis after pre-column derivatization of amino acids and small peptides. J Chromatogr A,1995,708��2��:309-321.
[11] CHEN J,LU Z,LAWRENCE T S,et al. Determination of WR-1065 in human blood by high-performance liquid chromatography following fluorescent derivatization by a maleimide reagent ThioGloTM3. J Chromatogr B Analyt Technol Biomed Life Sci,2005,819��1��:161-167.
[12] SHAW L M,BONNER H S,BROWN D Q. Metabolic pathways of WR-2721 (ethyol,amifostine) in the BALB/c mouse. Drug Metab Dispos,1994,22��6��:895-902.
[13] BONNER H S,SHAW L M. Measurement of both protein-bound and total S-2-��3-aminopropylamino��ethanethiol (WR-1065) in blood by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl,2000,739��2��:357-362.
[14] KORST A E,EELTINK C M,VERMORKEN J B,et al. Pharmacokinetics of amifostine and its metabolites in patients. Eur J Cancer,1997,33��9��:1425-1429.
[15] PENDERGRASS J A J R,SRINIVASAN V,KUMAR K S,et al. Determination of WR-1065 and WR-33278 by liquid chromatography with electrochemical detection. J Aoac Int,2002,85��3��:551-554.
[16] KORST A E,VERMORKEN J B,VAN DER VIJGH W J. High-performance liquid chromatographic assay using electrochemical detection for the combined measurement of amifostine,WR 1065 and the disulfides in plasma. J Chromatogr B Biomed Sci Appl,1997,693��1��:167-174.
[1] ������ ���� ����Ƽ ���� �ֵ���.ȥ��Һ���ǵ�������鵼�ĸΰ���֬���������ø�ٴ߻��ϳ��о�[J]. �й�ҩѧ��־, 2012,47(1): 40-43
[2] �ž�� ���� л�� �ž��� ����ƽ ���� �Ѹ�˳ ���ı�.HPLC-MS/MS�ⶨѪ���еı�����þ�����������ҩ��ѧ�о�[J]. �й�ҩѧ��־, 2011,46(5): 378-381
[3] ������ ���� ����Ԫ �����٩~.�����ǻ��Ǿ���-�������ż����ĺϳ������[J]. �й�ҩѧ��־, 2011,46(21): 1677-1680
[4] ������ ������ ����� .�������ǶԺ�ϸ��CR1������S180A��H22����С������ϸ����������Ӱ��[J]. �й�ҩѧ��־, 2011,46(18): 1405-1411
[5] ����÷ ;���� ;������ ;Ǯ���� ;���� ;�ݺ��� . ��ЧҺ��ɫ�׷��ⶨѪҺ����Һ�е���������Ũ��[J]. �й�ҩѧ��־, 2009,44(22): 1735-1737
[6] ����;����ɽ;������.���������ڷ��������Ӧ�õ��о���չ[J]. �й�ҩѧ��־, 2005,39(19): 1444-1448
[7] ��׿��;����Ӣ;����;���㲨.5��-��-4��-��-����-3��-����Һ���պϳ��о�[J]. �й�ҩѧ��־, 2003,38(04): 300-302
[8] ���;.����ڷ��Ҵ�����Һ��ȫѪ����ȩ�����IJⶨ[J]. �й�ҩѧ��־, 2002,22(10): 590-592
[9] �����;��һɺ;����÷;���;������;������;.��������껼�߾���Ѫ��ָѪ����Һ��Ũ�ȵ������[J]. �й�ҩѧ��־, 2002,22(05): 274-276
[10] ������ ֱ����˾ ƽҰ���� �ұ�ϲ���� ��צ�ŷ�.����ɳ�����������ϰ�������Һ�е���й[J]. �й�ҩѧ��־, 2000,35(12): 827-829
[11] �ž���;�ӻ�.��Һ�к˻���ҩ-ʱ���ߵIJⶨ[J]. �й�ҩѧ��־, 1999,34(02): 122-123
[12] �ܹ���;�޹���;����;ʷ��;����ܰ;������.��Чëϸ�ܵ�Ӿ���������˺�ϸ��������[J]. �й�ҩѧ��־, 1998,33(07): 424-426
[13] �ܹ�ӱ;�ﴺ��;������;���.��ﻼ��Ѫ���Ѫ�峬��Һ����Һ�б���Ӣ�ƺͿ�����ƽ��Ũ�Ȳⶨ[J]. �й�ҩѧ��־, 1996,31(02): 93-95
[14] ������;��;����;������;ë�Ǻ�.��Һ��ѪҺ�мغ�����������о�[J]. �й�ҩѧ��־, 1994,29(08): 478-480
[15] ������;������;�����;Ф�Ļ�.��˾ƥ�ֻ���Ƭ������[J]. �й�ҩѧ��־, 1990,25(02): 86-87
Copyright 2010 by �й�ҩѧ��־